Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Microspheres show positive results for uterine fibroid treatment

CeloNova BioSciences : 21 January, 2008  (New Product)
CeloNova BioSciences has released data from an 11 centre, eight country European study of uterine fibroid embolisation using the company's Embozene Microspheres.
Patients in the study were followed for six months. According to one of the principal investigators, Joachim Kettenbach, MD, Medical University of Vienna, 'Technical success was achieved in 98 percent of the patients. The side- effects of fibroids such as pain and heavy menstrual bleeding were significantly reduced while the patients' quality of life improved substantially.'

Embolisation is a minimally invasive procedure for uterine fibroids during which an interventional radiologist injects microspheres through a tiny Catheter to the site of the fibroid. The microspheres - each about the size of a period at the end of this sentence - block the blood flow to the fibroids causing them to atrophy. The procedure is an alternative for most women with fibroids to surgical procedures such as hysterectomy or myomectomy. Recovery time is measured in days rather than weeks.

CeloNova's Embozene Color-Advanced Microspheres are the only microspheres that are colour-coded by size. They have a hydrogel centre and an outer layer of the company's proprietary coating, Polyzene-F that enhances biocompatibility.

'From the beginning, CeloNova has operated on the principle that our products would give first-rate clinical outcomes for patients and meet the real-world needs of physicians,' said Thomas A Gordy, president and chief executive officer. Gordy continued, 'This study shows that Embozene Microspheres embody that philosophy; reducing patients' symptoms while improving their quality of life. Colour-coding improves Patient safety while simplifying the job of those performing the procedure.'

The The Sphere study results were reported at the 20th Annual International Symposium on Endovascular Therapy.
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo